Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (397)	6/1/2006 12:17:37 PM
From: tuck	Read Replies (1) \| Respond to of 447

I think some anticipation of ASCO buzz from Tarceva/Avastin combo in lung cancer is being baked into the stock already. Regarding the combo, the PII is probably not large enough to give it good odds of succeeding, IMO. And I'd guess the combo would be expensive, a tough sell to insurers if the benefit is not very clear. Adding fluffy Macugen news (plausible trading concept: sell any Macugen related bounce) . . . I wonder how much more room there is for OSIP to run. I see resistance at $30.5. I'm taking the gift now, though, because of the Lucentis data presentation tomorrow. Sold a batch of June 25 calls against my position (in a recent post, I said my June calls expired worthless; clearly a typo: I meant May). Cheers, Tuck